Clinical Trials at Indiana University Melvin and Bren Simon Comprehensive Cancer Center
As of June 2026, 32 paid clinical trials are recruiting at Indiana University Melvin and Bren Simon Comprehensive Cancer Center, located at Indiana University Melvin and Bren Simon Comprehensive Cancer Center, 535 Barnhill Dr, Indianapolis, IN 46202, phone (888) 600-4822 in Indianapolis, Indiana. Active studies at this site cover conditions such as Heart Failure, Breast Cancer and Obesity. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
32 clinical trials at Indiana University Melvin and Bren Simon Comprehensive Cancer Center
·Clear filters·↓ Download CSVImmuNe ParameTERs to Predict Immunotherapy REsponse and Toxicity (INTERPRET)
Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer
Circulating Tumor DNA in Stage I, II, and III Germ-Cell Tumors
Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
Maintenance Zanzalintinib With Etoposide After HDCT in GCT
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Long Term Follow-up Study for Subjects Administered CLBR001
ctHPVDNA in HPV Positive Squamous Cell Carcinoma of the Oropharynx
Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer
Evaluating Tolerability of ePUHRT With Brachytherapy Boost
Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer
Letrozole in Uterine Leiomyosarcoma
SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant
Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)
Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
Pre-Rehabilitation for Female Patients Undergoing Pelvic Radiotherapy
ASCVD Management Using CCTA in Prostate Cancer Patients on ADT
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer
Rapid Autopsy Protocol for Patients With Small Cell Lung Cancer
Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases
Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer
ATEMPT 2.0: Adjuvant T-DM1 vs TH
Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer
CD4CAR for CD4+ Leukemia and Lymphoma
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
About research studies in Indianapolis
Indianapolis has approximately 932 recruiting research studies across a wide range of therapeutic areas. Indiana hosts a diverse network of universities, academic medical centers, and community hospitals that run clinical trials across oncology, cardiology, neurology, and many other therapeutic areas.
Common conditions studied in Indianapolis
- Heart Failure (17 active studies). Heart failure trials explore SGLT-2 inhibitors, novel myosin modulators, and device-based therapies for both reduced and preserved ejection fraction.
- Breast Cancer (12 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- Obesity (12 active studies). Obesity trials evaluate GLP-1 and GIP receptor agonists, novel metabolic drugs, and combined lifestyle interventions for sustainable weight loss.
- Prostate Cancer (11 active studies). Prostate cancer studies test next-generation hormone therapies, PARP inhibitors, and radioligand treatments for both localized and advanced disease.
- Dementia (10 active studies). ENT (otolaryngology) trials evaluate new treatments for hearing loss, swallowing disorders, and head and neck cancers — covering pharmacologic, surgical, and rehabilitative approaches.
- Alzheimer Disease (9 active studies). Alzheimer's research investigates anti-amyloid antibodies, tau-targeted therapies, and lifestyle interventions aimed at slowing cognitive decline.
Leading research sponsors in Indianapolis
- Indiana University
- Eli Lilly and Company
- National Cancer Institute (NCI)
- Children's Oncology Group
- AbbVie
Local regulations and guidelines
Clinical trials in Indiana are governed by U.S. Food and Drug Administration (FDA) regulations, Office for Human Research Protections (OHRP) standards, and federal HIPAA privacy rules. Every study is reviewed by an Institutional Review Board (IRB) to protect participant safety and ensure informed consent. Indiana research additionally follows state public health department oversight and any applicable state privacy statutes.
Compensation & what to expect
- How payment typically works
- Compensation is most often provided through reloadable electronic study cards or direct deposit, paid out per completed visit rather than as a lump sum. Amounts vary by the time required, the number of visits, and the study's complexity — overnight stays and inpatient pharmacology studies generally pay more than short outpatient surveys. The exact amount is disclosed in writing during informed consent before any visit.
- Healthy volunteers
- Healthy participants aged 18 and older can earn compensation by joining vaccine, pharmacology, and biomarker studies in Indianapolis. These trials check how a new drug or vaccine behaves in healthy bodies before later-phase testing. Many sites maintain a healthy-volunteer registry so you hear about new opportunities first.
- What's included beyond payment
- Most trials cover study-related medical care at no cost — physical exams, lab work, imaging, the investigational treatment itself, and follow-up visits with the research team. Insurance is not required to participate. Free check-ups and access to specialists are common reasons participants return for additional studies.
- Travel and time
- Many sponsors reimburse travel, parking, mileage, and lost wages for visit days. Long-running studies and trials that require frequent visits often raise stipends accordingly. Ask the study coordinator for the visit schedule and reimbursement policy before you commit.
- Asking about compensation
- Compensation is set per protocol and per site, so figures are not published in trial registries. The fastest way to confirm payment for a specific study is to contact the recruiting site listed on the study record. Coordinators are accustomed to this question and will quote the per-visit and total amounts up front.
How to find a clinical trial in Indianapolis
Hipa.ai aggregates every recruiting study in Indianapolis from ClinicalTrials.gov and refreshes the list daily. Use the filters above to narrow by condition, facility, age, phase, or healthy-volunteer eligibility, then click any study title to view full details — eligibility criteria, intervention, location, and sponsor contact information. To enroll, reach out to the central study contact listed on the study detail page; the research coordinator will walk you through the screening process.
Frequently asked questions
How many paid clinical trials are currently recruiting in Indianapolis?
There are approximately 932 recruiting clinical trials in Indianapolis, Indiana listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Indianapolis pay participants?
Most recruiting trials in Indianapolis compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Indianapolis?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Indianapolis?
The most common conditions under active study in Indianapolis include Heart Failure (17), Breast Cancer (12), Obesity (12), Prostate Cancer (11), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Indianapolis?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Indianapolis on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Indianapolis?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Indianapolis?
Recruiting research sites in Indianapolis include Indiana University, Riley Hospital for Children, Indiana University School of Medicine, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Indianapolis right now?
The largest active categories in Indianapolis are Cancer & tumors (246), Cardiovascular (69), Diabetes & metabolic (50). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Indiana University Melvin and Bren Simon Comprehensive Cancer Center?
Indiana University Melvin and Bren Simon Comprehensive Cancer Center is located at Indiana University Melvin and Bren Simon Comprehensive Cancer Center, 535 Barnhill Dr, Indianapolis, IN 46202. Use the Google Maps link in the intro above to get directions.
How do I contact Indiana University Melvin and Bren Simon Comprehensive Cancer Center?
You can reach Indiana University Melvin and Bren Simon Comprehensive Cancer Center by phone at (888) 600-4822. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.